All In Biotech

Drug Trial Radar · NCT00356681

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination With Paclitaxel, or Open-Label Bevacizumab in Combination With Paclitaxel, as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 282 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

282

Actual

Start

Dec 2006

Primary completion

Feb 2009

Study completion Aug 2012

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jul 26, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if treatment with paclitaxel plus AMG 706 is superior to paclitaxel plus AMG 706 placebo in subjects with HER2 negative locally recurrent or metastatic breast cancer. Also to estimate differences between treatment with paclitaxel plus AMG 706 and paclitaxel plus bevacizumab.

Conditions

  • Breast Neoplasms
  • Breast Tumors
  • Breast Cancer
  • Locally Recurrent and Metastatic Breast Cancer

Interventions

  • AMG 706 placeboDrug

    Blinded placebo

  • BevacizumabDrug

    Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.

  • AMG 706Drug

    AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.

  • PaclitaxelDrug

    Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate, measured radiologically and assessed by an independent review committee.Time frame: Last patient enrolled + 16 weeks of treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.